You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
FIND said that the consortium will evaluate the impact on clinical trial participants of innovative diagnostic technologies versus current standards of care.
The collaboration will align diagnostic placement with treatment capacity for tuberculosis and HIV, among other diseases.
FIND also announced support for projects from Axxin and DNC Dx for point-of-care detection of sexually transmitted infections.
News items for the week of Oct. 28, 2019.
The project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa starting in October.
The test, called Fujifilm SILVAMP TB LAM, was found to be about 30 percent more sensitive than the Alere Determine TB LAM Ag test from Abbott.
The test for P. vivax-associated malaria was developed with support from FIND and will be distributed by Human Diagnostics Worldwide.
The two organizations will seek to engage stakeholders worldwide in order to increase demand for and access to HCV diagnostics.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
The agency plans to evaluate newer RDTs in the future, and it is collaborating to bring molecular testing nearer to patients.